SGLT2阻害剤の市場規模、シェア、動向分析レポート：薬剤別、適応症別、流通チャネル別、地域別、セグメント予測、2024年～2030年

SGLT2阻害剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、SGLT2阻害剤の世界市場規模は2030年までに294億3,000万米ドルに達すると予測され、予測期間中にCAGR 7.71％で拡大する見込みです。

米国糖尿病学会（ADA）、欧州糖尿病学会（EASD）、欧州心臓病学会（ESC）などの主要な医療機関からの推奨や支持ガイドラインは、グルコースコントロールを超えたナトリウムグルコース共輸送体2（SGLT2）阻害薬を支持しています。例えば、2023年8月、欧州心臓病学会（ESC）は、EMPEROR-Preserved、DELIVER、STRONG-HF、IRONMANなど、2021年以降に実施された12近くの新しい臨床試験から得られた知見を統合し、心不全ガイドラインの重点的な更新を発表しました。ESC Congress 2023で発表された最新のガイドラインでは、軽度に駆出率が低下した心不全（HFmrEF）患者の治療におけるSGLT2阻害剤の使用に関する新たな推奨事項が紹介されています。

また、今後数年間で透析を必要とする患者数が増加することから、CKD患者の治療にSGLT2阻害剤などの医薬品の需要が高いことが示されました。2023年11月、NICE（National Institute for Health and Care Excellence）は、慢性腎臓病（CKD）患者に対するSGLT2阻害剤であるエンパグリフロジンの使用を推奨するガイダンス案を発表しました。エンパグリフロジンは、腎不全への進行を遅らせ、心臓発作や脳卒中のリスクを減少させる有効性が実証されています。NICEは、この治療をCKDのあらゆる病期の患者に提供することを推奨しています。このような医薬品規制機関の勧告は、予測期間中の医薬品需要を押し上げると予想されます。

高齢者は2型糖尿病や心不全に罹患しやすく、薬剤が大きな効果を示す疾患です。このような人口動態の変化により、SGLT2阻害剤のような効果的な治療薬に対する需要が高まっています。SGLT2阻害剤は、特に高齢者に多い心血管リスクや腎リスクを軽減するのに有効です。この利点により、これらの薬剤は高齢の患者にとって好ましい選択肢となっています。世界保健機関（WHO）によると、2022年には約14億人が60歳以上の高齢者となり、2020年の10億人から増加します。さらにWHOは、高齢者人口が21億人に達すると予測しています。このように、高齢者人口の増加はSGLT2阻害剤の世界の需要を押し上げ、市場成長を促進すると予想されます。

患者と医療従事者の双方における糖尿病に対する認識と治療におけるSGLT2阻害剤の意義の高まりは、処方率の向上に寄与しています。例えば、WHOは2021年に、SGLT2阻害剤やインスリンを含む糖尿病治療薬に対する認知度を高め、患者のアクセスを改善するためのイニシアチブ「Global Diabetes Compact」を開始しました。このようなイニシアチブは、SGLT2阻害剤の採用を促進し、予測期間中に市場に新たな機会を開くと期待されます。

SGLT2阻害剤市場レポートハイライト

• ジャーディアンス（エンパグリフロジン）セグメントは2023年に市場を席巻し、予測期間中に大きく成長すると予測されます。この成長は、糖尿病、CKD、心血管疾患の有病率の増加と治療に対する高い薬剤需要によるものです。
• 2023年には、2型糖尿病セグメントが市場を独占しました。この優位性は、糖尿病の罹患率の上昇、老人人口の増加、薬剤の処方率の増加によるものです。
• 病院薬局セグメントが2023年の市場を独占しました。この優位性は、糖尿病、CKD、心不全患者の診断と治療のための入院数の増加によるものです。
• 北米は、高度なヘルスケアインフラ、対象疾患の有病率の上昇、良好な規制環境などの要因により、市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 SGLT2阻害剤市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• SGLT2阻害剤市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析
  • 対象人口分析

第4章 SGLT2阻害剤市場：薬剤別推定・動向分析

• 世界のSGLT2阻害剤市場：薬剤別ダッシュボード
• 世界のSGLT2阻害剤市場：薬剤別変動分析
• 世界のSGLT2阻害剤市場：薬剤別収益
• ジャディアンス（エンパグリフロジン）
• ファルシーガ（ダパグリフロジン）
• インボカナ（カナグリフロジン）
• インペファ（ソタグリフロジン）
• Qtern（ダパグリフロジン/サキサグリプチン）
• その他のSGLT2阻害剤

第5章 SGLT2阻害剤市場：適応症別推定・動向分析

• 世界のSGLT2阻害剤市場：適応症別ダッシュボード
• 世界のSGLT2阻害剤市場：適応症別変動分析
• 世界のSGLT2阻害剤市場：適応症別収益
• 2型糖尿病
• 心臓血管
• 慢性腎臓病（CKD）
• その他

第6章 SGLT2阻害剤市場：流通チャネル別推定・動向分析

• 世界のSGLT2阻害剤市場：流通チャネル別ダッシュボード
• 世界のSGLT2阻害剤市場：流通チャネル別変動分析
• 世界のSGLT2阻害剤市場：流通チャネル別収益
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 SGLT2阻害剤市場：薬剤、適応症、流通チャネル別の地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネル パートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023 年
  • Boehringer Ingelheim International GmbH.
  • AstraZeneca
  • Merck &Co., Inc.
  • Johnson &Johnson Services, Inc.（Janssen Pharmaceuticals, Inc.）
  • TheracosBio, LLC
  • Lexicon Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Ltd

List of Tables

• Table 1 List of abbreviation
• Table 2 North America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 3 North America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 4 North America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 U.S. SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 7 U.S. SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 9 Canada SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 10 Canada SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 12 Mexico SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 13 Mexico SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Europe SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 17 Europe SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 19 Germany SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 20 Germany SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 22 UK SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 23 UK SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25 France SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 26 France SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 27 France SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 Italy SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 29 Italy SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 31 Spain SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 32 Spain SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 Denmark SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 35 Denmark SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 Sweden SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 38 Sweden SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Norway SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 41 Norway SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 47 China SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 48 China SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 49 China SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50 Japan SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 51 Japan SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 53 India SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 54 India SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 55 India SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 56 South Korea SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 57 South Korea SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 59 Australia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 60 Australia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62 Thailand SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 63 Thailand SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 65 Latin America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 66 Latin America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 67 Latin America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 69 Brazil SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 70 Brazil SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 72 Argentina SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 73 Argentina SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75 MEA SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 76 MEA SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 77 MEA SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79 South Africa SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 80 South Africa SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 85 UAE SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 86 UAE SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
• Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
• Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 SGLT2 Inhibitors market: market outlook
• Fig. 14 SGLT2 Inhibitors competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 SGLT2 Inhibitors market driver impact
• Fig. 18 SGLT2 Inhibitors market restraint impact
• Fig. 19 SGLT2 Inhibitors market: Drug movement analysis
• Fig. 20 SGLT2 Inhibitors market: Drug outlook and key takeaways
• Fig. 21 Jardiance (empagliflozin) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Farxiga (dapagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Steglatro (ertugliflozin) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Invokana (canagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Brenzavvy (bexagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Inpefa (sotagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Other SGLT2 inhibitors estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 SGLT2 Inhibitors market: Indication movement analysis
• Fig. 29 SGLT2 Inhibitors market: Indication outlook and key takeaways
• Fig. 30 Type 2 diabetes market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Chronic kidney disease (CKD) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 SGLT2 Inhibitors market: Distribution channel movement analysis
• Fig. 35 SGLT2 Inhibitors market: Distribution channel outlook and key takeaways
• Fig. 36 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Global SGLT2 Inhibitors market: Regional movement analysis
• Fig. 40 Global SGLT2 Inhibitors market: Regional outlook and key takeaways
• Fig. 41 Global SGLT2 Inhibitors market share and leading players
• Fig. 42 North America, by country
• Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 U.S. key country dynamics
• Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Canada key country dynamics
• Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Mexico key country dynamics
• Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 UK key country dynamics
• Fig. 52 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Germany key country dynamics
• Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 France key country dynamics
• Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Italy key country dynamics
• Fig. 58 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Spain key country dynamics
• Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Denmark key country dynamics
• Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Sweden key country dynamics
• Fig. 64 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Norway key country dynamics
• Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 China key country dynamics
• Fig. 69 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Japan key country dynamics
• Fig. 71 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 India key country dynamics
• Fig. 73 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Thailand key country dynamics
• Fig. 75 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 South Korea key country dynamics
• Fig. 77 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Australia key country dynamics
• Fig. 79 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Brazil key country dynamics
• Fig. 82 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Argentina key country dynamics
• Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 South Africa key country dynamics
• Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Saudi Arabia key country dynamics
• Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 UAE key country dynamics
• Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Kuwait key country dynamics
• Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Market share of key market players - SGLT2 Inhibitors market

SGLT2 Inhibitors Market Growth & Trends:

The global SGLT2 inhibitors market size is anticipated to reach USD 29.43 billion by 2030 and is expected to expand at a CAGR of 7.71% during the forecast period, according to a new report by Grand View Research, Inc. The recommendations and supportive guidelines from major health organizations, such as the American Diabetes Association (ADA), the European Association of for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and others have endorsed sodium-glucose cotransporter-2 (SGLT2) inhibitors for them beyond glucose control. For instance, in August 2023, the European Society of Cardiology (ESC) has issued a focused update to their heart failure guidelines, integrating findings from nearly a dozen new clinical trials since 2021, such as EMPEROR-Preserved, DELIVER, STRONG-HF, and IRONMAN. Released at the ESC Congress 2023, the updated guidelines introduce new recommendations for the use of SGLT2 inhibitors in treating patients with heart failure with mildly reduced ejection fraction (HFmrEF).

In addition, the growing number of patients needing dialysis over the next few years showcased high demand of medicines such as SGLT2 inhibitors for treatment of CKD patients. In November 2023, the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of empagliflozin, an SGLT2 inhibitor, for patients with chronic kidney disease (CKD). Empagliflozin has demonstrated efficacy in slowing the progression to kidney failure and reducing the risk of heart attacks and strokes. NICE recommends making this treatment available to patients across all stages of CKD. Such recommendations from drug regulatory agencies are expected to boost demand for drugs during the forecast period.

The elder adults are more prone to type 2 diabetes and heart failure, conditions where drugs have shown substantial benefits. This demographic shift increases the demand for effective treatments such as SGLT2 inhibitors. SGLT2 inhibitors are beneficial in reducing cardiovascular and renal risks, which are particularly prevalent in the elderly. This advantage makes these medications a preferred choice for older patients. According to the World Health Organization (WHO), in 2022, around 1.4 billion people were aged 60 years and over, which was raised from 1 billion in 2020. In addition, WHO estimates that the elderly population is expected to reach 2.1 billion. Thus, rising geriatric population is expected to boost demand for SGLT2 inhibitors worldwide and drive market growth.

Increasing awareness of diabetes and significance of SGLT2 inhibitors in treatment among both patients and healthcare providers contribute to higher prescription rates. For instance, in 2021, the WHO launched initiative "Global Diabetes Compact" to raise awareness and improve patient access to diabetic medicine including SGLT2 inhibitors and insulin. Such initiatives are expected to boost adoption of SGLT2 inhibitors and open new opportunities in the market over the forecast period.

SGLT2 Inhibitors Market Report Highlights:

• Jardiance (empagliflozin) segment dominated the market in 2023 and is anticipated to grow significantly over the forecast period. This growth is attributed due to increasing prevalence of diabetes, CKD, and cardiovascular conditions and high drug demand for treatment
• Type 2 diabetes segment dominated the market in 2023. This dominance is attributed due to rising incidence of diabetes, increasing geriatric population, and increased prescription rate of drug
• Hospital pharmacies segment dominated the market in 2023. This dominance is attributed due to increasing number hospitalization of diabetes, CKD, and heart failure patients for diagnosis and treatment
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Indication
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug and Indication outlook
  • 2.2.2. Distribution Channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of target disease
    • 3.2.1.2. Technological advancements in drug development
    • 3.2.1.3. Growing awareness and diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of drug development
    • 3.2.2.2. Stringent regulatory policies for drug approval
• 3.3. SGLT2 Inhibitors Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

• 4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
• 4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
• 4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
• 4.4. Jardiance (empagliflozin)
  • 4.4.1. Jardiance (empagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Farxiga (dapagliflozin)
  • 4.5.1. Farxiga (dapagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Invokana (canagliflozin)
  • 4.6.1. Invokana (canagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Inpefa (sotagliflozin)
  • 4.7.1. Inpefa (sotagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Qtern (dapagliflozin/saxagliptin)
  • 4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Other SGLT2 Inhibitors
  • 4.9.1. Other SGLT2 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

• 5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
• 5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
• 5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
• 5.4. Type 2 Diabetes
  • 5.4.1. Type 2 diabetes market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cardiovascular
  • 5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Chronic Kidney Disease (CKD)
  • 5.6.1. Chronic kidney disease (CKD) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
• 6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
• 6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Boehringer Ingelheim International GmbH.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. AstraZeneca
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Merck & Co., Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. TheracosBio, LLC
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Lexicon Pharmaceuticals, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Eli Lilly and Company
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Bristol-Myers Squibb Company
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Glenmark Pharmaceuticals Ltd
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives